Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy

Acta Oncologica

Volumn 51, Issue 1, 2012, Pages 86-96

  Garske, Ulrike ^a   Sandström, Mattias ^b   Johansson, Silvia ^b   Sundin, Anders ^b   Granberg, Dan ^b   Eriksson, Barbro ^b   Lundqvist, Hans ^c  

^a Department of Radiology Oncology and Radiation Science   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; LUTETIUM 177; OCTREOTIDE;

ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HUMAN; KIDNEY; LIVER; MALE; MEASUREMENT; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN;

DOSE FRACTIONATION; FEMALE; HALF-LIFE; HUMANS; KIDNEY; LIVER; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANS AT RISK; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SPLEEN; TREATMENT OUTCOME;

EID: 83455181719     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.618511     Document Type: Article

References (23)

1. Kwekkeboom DJ., Bakker WH., Kooij PP., Konijnenberg MW., Srinivasan A., Erion JL., et al. [177Lu-DOTAOTyr3]octreo-tate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
2. Barone R., Borson-Chazot F., Valkema R., Walrand S., Chauvin F., Gogou L., et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(Suppl 1):99S-106S. (Pubitemid 47619025)
3. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzen-rider JE., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
4. Sandstrom M., Garske U., Granberg D., Sundin A., Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010;37:212-25.
5. Bodei L., Cremonesi M., Grana C., Rocca P., Bartolomei M., Chinol M., et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendo-crine tumours. Eur J Nucl Med Mol Imaging 2004;31: 1038-1046. (Pubitemid 38915663)
6. Cremonesi M., Botta F., Di Dia A., Ferrari M., Bodei L., De Cicco C., et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 2010;54:37-51.
7. Wessels BW., Konijnenberg MW., Dale RG., Breitz HB., Cremonesi M., Meredith RF., et al. MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response -implications for radionuclide therapy. J Nucl Med 2008;49:1884-99.
8. Rolleman EJ., Melis M., Valkema R., Boerman OC., Krenning EP., de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010;37:1018-31.
9. Kwekkeboom DJ., Teunissen JJ., Bakker WH., Kooij PP., de Herder WW., Feelders RA., et al. Radiolabeled somatosta-tin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23:2754-62. (Pubitemid 46179465)
10. Kwekkeboom DJ., de Herder WW., Kam BL., van Eijck CH., van Essen M., Kooij PP., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity., efficacy., and survival. J Clin Oncol 2008;26: 2124-30.
11. Dieudonne A., Hobbs RF., Bolch WE., Sgouros G., Gardin I. Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size. J Nucl Med 2010;51: 1600-7.
12. Ljungberg M., Frey E., Sjogreen K., Liu X., Dewaraja Y., Strand SE. 3D absorbed dose calculations based on SPECT: Evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm 2003;18:99-107. (Pubitemid 36307471)
13. Wilderman SJ., Dewaraja YK. Method for fast CT/SPECT-Based 3D Monte Carlo absorbed dose computations in internal emitter therapy. IEEE Trans Nucl Sci 2007;54: 146-51. (Pubitemid 46375854)
14. Ljungberg M., Sjogren-Gleisner K. The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study. Acta Oncol 2011 Aug;50: 981-9.
15. S.Y.F. Chu LPEaRBF [Internet]. The Lund/LBNL Nuclear Data Search. 1999 [cited 2011 Aug 23]. Available from: http://nucleardata.nuclear.lu.se/ nucleardata/toi/
16. Helisch A., Forster GJ., Reber H., Buchholz HG., Arnold R., Goke B., et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3- octreotide versus 111In-pentetre-otide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386-92. (Pubitemid 39361934)
17. Therasse P., Eisenhauer EA., Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9.
18. Flux G., Bardies M., Chiesa C., Monsieurs M., Savolainen S., Strand SE., et al. Clinical radionuclide therapy dosimetry: The quest for the "Holy Gray". Eur J Nucl Med Mol Imaging 2007;34:1699-700. (Pubitemid 47476925)
19. Behr TM., Sharkey RM., Juweid ME., Blumenthal RD., Dunn RM., Griffiths GL., et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55: 3825-34.
20. Rolleman EJ., Valkema R., de Jong M., Kooij PP., Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15. (Pubitemid 36692887)
21. Jamar F., Barone R., Mathieu I., Walrand S., Labar D., Carlier P., et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) -a phase 1 clinical study: Pharmacokinetics., biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-8. (Pubitemid 36559829)
22. Valkema R., Pauwels SA., Kvols LK., Kwekkeboom DJ., Jamar F., de Jong M., et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0)., Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl 1):83S-91S. (Pubitemid 47619023)
23. Konijnenberg M., Melis M., Valkema R., Krenning E., de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134-42. (Pubitemid 47555387)